AI in Pharma: Discovery
7th Annual

AI in Pharma: Discovery

Showcasing the Revolutionary Advancements of AI in Drug Discovery

Wednesday, October 4th 2023 | Boston, MA

As Part of the Future of R&D Week | October 3rd-5th

Register Agenda
Future of R&D Week
October 3rd

The scientific community aims for there to be a day where no target is hard-to-drug, but this will not come without exploration of new methods, approaches and cross-company partnerships. Kicking-off the co-located Future of R&D Event Week (3rd-5th October), Next Generation Undruggable 2023 uniquely aims to be the focal point for pharmaceutical and biotechnology companies, academics and investors alike to discuss the most pressing scientific and commercial issues facing the industry in 2023.

 

Find Out More

October 4th

AI-based technology has undergone a recent dramatic revolution, with AI in drug discovery being projected to reach a market value of $8.95 billion by 2030. The 7th annual AI in Pharma: Discovery Summit offers a unique platform for leading experts, innovators, and industry professionals to stay at the forefront of the AI revolution within the pharmaceutical and biotechnology industry. This one-day summit, as part of the co-located Future of R&D Event Week (3rd-5th October), is dedicated to exploring how AI, ML, NLP, data science and generative deep learning models can be used to determine protein structure, identify targets, optimize lead generation and generate predictive models.

 

Find Out More

October 5th

AI technologies have the potential to totally transform how the pharmaceutical industry approaches clinical trials and development by providing new opportunities and helping to decrease risks associated with clinical trials and development. AI in Pharma: Clinical Development 2023, the final day of the co-located Future of R&D Event Week (3rd-5th October), will showcase these ground-breaking advancements in the implementation and utilization of AI, clinical modeling and data science to streamline and accelerate clinical R&D.

 

Find Out More

Previous 2022 Partners

Title Partner
Title Partner
Knowledge Partners
Knowledge Partner
Knowledge Partner

Twill is The Intelligent Healing Company™. We shorten the distance between need and care by configuring personalized digital therapeutics and care solutions at scale for the modern healthcare cloud. Our platform integrates AI with empathy, making healing more personal, precise, and connected for the entire care journey. We deploy a full spectrum of clinical-grade care solutions—including Digital Therapeutics, Coaching, Community, and Well-being products—for pharma, health plans, enterprises, and individuals everywhere.

Our global platform is available in 10 languages, supports more than 10 chronic conditions, and covers more than 20 million lives.

Learn More

Knowledge Partner

QC Ware enables enterprises to leverage the latest computational power to accelerate innovation while preparing them for quantum supremacy. A quantum market leader, they offer software and services across biotech and pharmaceuticals, financial services, aerospace, energy, and more. Clients include Roche, Boehringer Ingelheim, Covestro, Goldman Sachs, and BMW. QC Ware is the organizer of Q2B, the first and largest gathering of the international quantum computing community.

Knowledge Partners

Our physics-based computational platform leverages a deep understanding of physics, chemistry, and predictive modeling to accelerate innovation.

Our platform enables our collaborators to discover high-quality, novel molecules more rapidly, at lower cost, and we believe with a higher likelihood of success compared to traditional methods. We’re also harnessing this platform for our internal drug discovery programs.

We are proud to be leading this digital revolution.

Learn More

Summit Partners
Summit Partner

Agnostiq is developing Covalent, an open source workflow orchestration platform designed to help users manage and execute tasks on heterogeneous compute resources.

Learn More

Summit Partner
Summit Supporter
Summit Supporter

Genomenon’s AI-driven genomic engine leverages billions of genetic associations between diseases, phenotypes, and therapies found within the medical evidence. They deliver a comprehensive genomic landscape for every disease, including rare, neurodegenerative, and genetic diseases, as well as somatic and germline cancer.

Armed with a comprehensive base of molecular biomarkers and disease mechanisms, Genomenon’s customers expand their genetic knowledge of the disease drivers by a factor of 10-20X to accelerate target discovery, identify genetic biomarkers for better clinical trial stratification, and develop CDx for regulatory approval

Learn More

Crucial Topics

Decode the biggest challenges and opportunities in the applications and adoption of AI, ML and Data Science within drug discovery. Join crucial conversations covering topics including how the culture around AI should be managed, using generative deep learning models, leveraging AI for predictive modeling, how to overcome challenges within data analytics and how it is best to invest into AI.

Build Valuable Connections

Explore new collaborations with senior leaders from across the pharmaceutical industry by joining prevalent discussions and having the opportunity to openly exchange thoughts and ideas. Gain exclusive insights from those showcasing cutting edge developments, including from Takeda, Sanofi, Novartis, AstraZeneca and more.

Day Two of the Future of R&D Week

Next-Generation Undruggable, AI in Pharma: Discovery and AI in Pharma: Clinical Development, will provide a comprehensive offering, bringing the industry together to delve into the latest developments and future of R&D. Kick-off by exploring the future of difficult-to-drug disease, then deep-dive into the application of AI in early stage R&D before focus shifts to the AI transformation of clinical development and trials.

 I’m looking forward to participating in this meeting to advance the discussion on how we can leverage AI to transform the trajectory of healthcare. AI is fundamentally changing how we innovate – enabling us to accelerate R&D and drive greater patient impact than ever before.

Tomasso Mansi, Vice President, Artificial Intelligence, Machine Learning & Digital Health, Janssen Research & Development

This year alone, we’ve witnessed a surge of AI breakthroughs at an unprecedented pace, making the immense potential of AI increasingly undeniable. There is no sector this technology doesn’t touch. I am eager to attend the AI summit where I expect to witness the unveiling of imaginative approaches that continue to shape a brighter future.

Hannah Gordon, VP of Product, Endeva Biosciences

With so many breathtaking new announcements of truly remarkable advances in AI algorithms, the industry continues to share ever-heightening expectations for the promise of AI to deliver on the many diverse scientific and operational challenges that face drug discovery and development. I’m looking forward to hearing how my colleagues are succeeding (and failing too) at such efforts, and what we can learn from each.

Aaron Mackey, VP, Head of AI and ML, Sonata Therapeutics

2023 Speaker Faculty

Wade Davis
Wade Davis
VP of Computational Sciences
Moderna
Wade Davis
VP of Computational Sciences
Moderna

Wade Davis is VP of Computational Science at Moderna. He holds a PhD in Statistics and completed an NIH Fellowship in Biomedical Informatics. Afterwards, he began his career in academia at Baylor University and then University of Missouri School of Medicine, where he was a tenured Associate Professor. Wade has received research funding from dozens of federal research grants and served on the editorial board for the Journal of the American Statistical Association. Wade then joined AbbVie, where he took roles of increasing responsibility and ultimately became Global Head of Bioinformatics and Computational Biology. Later, he was VP of Analytics and AI at Karius, a late-stage start-up using artificial intelligence for unbiased diagnosis of pathogens using microbial cell-free DNA. In his current position at Moderna, he leads wet and dry lab teams using computational methods to solve complex problems in R&D. Throughout his career, Wade and his teams have received many awards and he has given multiple conference keynotes. He has authored 100+ publications with dozens focused on target identification, predicting target-indication success, mechanism of action, and precision medicine.

Xiong Liu
Xiong Liu
Director of Data Science and AI
Novartis
Xiong Liu
Director of Data Science and AI
Novartis

Dr. Xiong Liu is a Director of Data Science and AI at Novartis. He was previously a principal data scientist and NLP lead at Eli Lilly. In the past 10 years, Dr. Liu has led data and AI programs to accelerate drug development, from early discovery to clinical trials and post-marketing research. His work has broad applications across the pharma value chain and impacted several marketed drugs. Prior to Pharma, he has won multiple Small Business Innovation Research awards from US government agencies for his research in data mining and informatics. He received his Ph.D. in Information Science from the University of Pittsburgh and did postdoctoral work in Bioinformatics at Johns Hopkins University.

Shruthi Bharadwaj
Shruthi Bharadwaj
Global Lead, Digital & Analytics, R&D Global Operations
Sanofi
Shruthi Bharadwaj
Global Lead, Digital & Analytics, R&D Global Operations
Sanofi
Nishtha Jain
Nishtha Jain
Head of Innovation and Digital Technology
Takeda
Nishtha Jain
Head of Innovation and Digital Technology
Takeda

Nishtha Jain is a strategic, innovative, and futuristic leader with 13+ years of global information technology experience in driving strategic business partnerships, digital technology and platform transformation and innovation in biopharma with past employers – Biogen and GlaxoSmithKline. Experienced in wide range of industry verticals ranging from Healthcare IT, Consulting, Biotech, Pharmaceutical and Vaccine industry– R&D Clinical, R&D Quality, Drug Development, Regulatory, Manufacturing, Medical and Commercial. Trusted adviser to executive leadership seeking to solve highly complex enterprise business challenges in fast-paced, rapidly changing, and challenging environments.

 

Nishtha is currently Head of Innovation and Digital Technology at Takeda Pharmaceuticals where her role expands across Global R&D Quality in driving digital and data initiatives from concept to execution leveraging emerging technologies and design principles. She has a strong passion for not only for applying emerging and digital technologies in improving patient healthcare but also for diversity and inclusion initiatives. She is currently member of Chief and serves as President for Healthcare Businesswomen’s Association’s (HBA) Mid- Atlantic chapter.

Hannah Gordon
Hannah Gordon
VP of Product
Enveda Biosciences
Hannah Gordon
VP of Product
Enveda Biosciences

Hannah’s expertise encompasses disease biology and leveraging AI and ML technology to link the right tools to the biggest opportunities in drug discovery. Working with multiple cross-functional teams at Enveda, Hannah’s exceptional ability to establish and implement effective processes and infrastructure enables her to harmonize the strengths of various disciplines.  Outside of her work at Enveda, Hannah enjoys spending time with her family, yoga, backcountry piloting, and exploring the beautiful mountains of Boulder.

Kyle Kaniecki
Kyle Kaniecki
VP of Life Sciences and Healthcare
NYC Economic Development Corporation
Kyle Kaniecki
VP of Life Sciences and Healthcare
NYC Economic Development Corporation

Kyle Kaniecki, PhD, is a Vice President of Life Sciences and Healthcare at the NYC Economic Development Corporation where he works to help implement the mayor’s $1B LifeSci NYC initiative by supporting translational R&D and accelerating startup formation, IP creation, and job growth. Before joining NYCEDC, Kyle was Director of Operations for Perception Neuroscience, a VC-backed neuropharmacology company where he led preclinical development.  He spent years at Columbia Technology Ventures supporting licensing activities and startups coming from Columbia University and led the development of the companion diagnostic for the blockbuster drug, Kalydeco.  Kyle earned his PhD in Genetics & Development from Columbia University, his MS in Biotechnology from the Johns Hopkins University, and his BS in Zoology from UW-Madison. 

Aaron Mackey
Aaron Mackey
VP of Data & AI/ML
Sonata Therapeutics
Aaron Mackey
VP of Data & AI/ML
Sonata Therapeutics

Aaron Mackey, PhD, is VP of Data & AI/ML at Sonata Therapeutics, where he leads all data engineering, modeling, and insight delivery activities in support of Sonata’s therapeutic development programs and the underlying proprietary biology platform used to identify novel targeted therapeutic candidates that induce immunogenic tumor cell death. Aaron’s 20+ years of career experience have spanned many diverse academic and industrial positions, large pharma and small biotech companies, preclinical and clinical organizations, and scientific and operational management. Originally trained as a wet-bench cellular immunologist, he chose to use his long-standing academic skills and interests with computer science and statistics to cross-train as a computational biologist during the era of the Human Genome Project and is now a generalist in pharma-related AI/ML methods and applications. A frequent speaker and open-source community mentor, he continues to hunt opportunities to mine multiomic data in search of mechanistic hypotheses that reveal disease-relevant (and therapeutically exploitable) insights. Aaron received his B.A. in Biochemistry and Molecular Biology from Reed College; his M.S. in Immunology from Washington University in St. Louis; and his PhD in Microbiology from the University of Virginia, with a short postdoc at the Penn Genomics Institute of the University of Pennsylvania, where he developed the first methods for statistically integrated, consensus eukaryotic gene structure prediction.

Ryan Emerson
Ryan Emerson
VP of Data Science
A-Alpha Bio
Ryan Emerson
VP of Data Science
A-Alpha Bio

Ryan is a computational biologist with over a decade of experience designing algorithms and pipelines for analyzing high-throughput sequencing data at scale and building machine learning models with large sequence datasets. He has led the development and launch of computational infrastructure for multiple platform technologies and clinical products. As VP of Data Science at A-Alpha Bio, Ryan leads the development and application of AlphaBind, utilizing the immense size and quantitative resolution of AlphaSeq data to build ML models that accelerate the design and optimization of new therapeutics.  Prior to joining A-Alpha, Ryan led the Computational Biology department and the Antigen Map project at Adaptive Biotechnologies.  Ryan earned his PhD in Genome Sciences from the University of Washington School of Medicine and his MBA from the Foster School of Business at the University of Washington.

Bradley Parry
Bradley Parry
Head of Artificial Intelligence
AI Therapeutics
Bradley Parry
Head of Artificial Intelligence
AI Therapeutics

Brad Parry, Ph.D. is the Head of Artificial Intelligence at AI Therapeutics. Dr. Parry graduated with a Ph.D. from Yale University in the lab of Christine Jacobs-Wagner where he pursued questions in biological physics concerning single living cells. To answer these questions, he developed novel experimental and computational approaches based in machine learning and deep learning to investigate the physical nature of the cytoplasm. After completing his degree, he continued developing and applying deep learning based approaches to investigate questions in cell biology as a research scientist at Yale. He now leads efforts to develop new datasets, algorithms and predict novel disease treatments as the Head of AI at AI Therapeutics.

Camilo Zapata
Camilo Zapata
Senior Director, Global Advanced Analytics and Data Management
AstraZeneca
Camilo Zapata
Senior Director, Global Advanced Analytics and Data Management
AstraZeneca

Camilo is a data scientist currently leading the commercial advanced analytics team supporting the biologics business unit at Astrazeneca. Before Astrazeneca he led the commercial advanced analytics organization at Alkermes, the compliance analytics efforts at Pfizer and the text mining and natural language processing hub at Lilly. He also co-led the creation of the advanced business analytics group at Lilly and he was responsible for building the analytical capabilities of Lilly’s clinical supply chain organization. 

Camilo is an engineer by training with M.S. degrees in Chemical and industrial engineering and a PhD in Chemical engineering from Purdue University.

Dorottya Nagy-Szakal
Dorottya Nagy-Szakal
Research Assistant Professor
SUNY Downstate Health Sciences University
Dorottya Nagy-Szakal
Research Assistant Professor
SUNY Downstate Health Sciences University

Dr. Nagy-Szakal has 15+ years of experience in translational medicine and microbiology, extensively focused on clinical metagenomics using NGS-based technologies powered by AI. She led cutting-edge clinical trials on fecal microbiota transplantation, gut-brain axis, multi-omics studies and the COVID-19 pandemic response with the ultimate goal of improving diagnostics and developing novel therapies. She currently holds a position as a Research Assistant Professor at SUNY Downstate Health Sciences University, and also the Chief Medical Officer at Biotia, where she drives strategic communications with the FDA, CDC, NYS DOH, leading enterprise medical centers and is responsible for the clinical operations, medical affairs and clinical/R&D laboratory operations. She earned her MD and PhD in clinical medicine from Semmelweis University of Medicine in Hungary, and held postdoctoral fellowships at Baylor College of Medicine/Texas Children’s Hospital and Columbia University.

Han Chang
Han Chang
Senior Director, Head of Late Stage Oncology, Translational Bioinformatics
Bristol Myers Squibb
Han Chang
Senior Director, Head of Late Stage Oncology, Translational Bioinformatics
Bristol Myers Squibb

Han Chang is a seasoned leader of computational biology and data science with strong leadership skills, extensive experience in biopharma R&D, and proven track record of making critical impacts on discovery, translational, and clinical strategies. He leads a team of analysts; applying cutting-edge bioinformatics, statistics, and machine learning methods; to work with clinical and large-scale data sets from BMS’s industry-leading late stage oncology pipeline, thus influencing development strategies and advancing the BMS late clinical oncology pipeline.

Mani Mohindru
Mani Mohindru
Chief Executive Officer
Novasenta
Mani Mohindru
Chief Executive Officer
Novasenta

Dr. Mohindru is the Chief Executive Officer and Board Member of Novasenta, Inc. a privately held biotechnology company focused on the discovery of novel targets to develop innovative therapies for cancers. She also serves as a member of the board of directors of CytomX Therapeutics and Cardiff Oncology. Prior to Novasenta, she has held senior leadership positions in the biotech industry, having served as Chief Executive Officer of CereXis, Inc. (private), Chief Financial Officer and Chief Strategy Officer of Cara Therapeutics, Inc. (public), and Chief Strategy Officer of Curis, Inc (public). 

Prior to her leadership roles in the biotechnology industry, Dr. Mohindru spent several years as an equity research analyst covering the biotechnology sector at UBS, Credit Suisse and ThinkEquity. She also co-founded a private biotechnology company and was a healthcare industry consultant. On the non-profit side, she is a member of the Executive Advisory Board of the Chemistry of Life Processes Institute of Northwestern University and a member of the Scientific Investment Advisory Committee of the Gates Center of Regenerative Medicine at the University of Colorado. 

Dr. Mohindru received her Ph.D. in Neurosciences from Northwestern University and her Masters in Biotechnology and BS in Human Biology (Hons) from the All India Institute of Medical Sciences, India.

Mehdi Sarmady
Mehdi Sarmady
Head of Data Science
Spark Therapeutics
Mehdi Sarmady
Head of Data Science
Spark Therapeutics

Partner With Us

Bringing together senior-level executives from across the industry, AI in Pharma: Discovery promises an unrivalled networking and learning opportunity for everyone working in this space.

AI in Pharma: Discovery provides a rare opportunity to showcase your offering to a dedicated, world-class audience. Spaces are limited this year, please contact our commercial manager, Elliott (elliott@greygreenmedia.com) to discuss opportunities for involvement.

Contact Us +
Partner With Us

Register for the Event

For pricing and booking options please click the button to go to the registration page.

Registration